Even making some allowance for distraction caused by the board changes, which RV denied was an issue anyway, the lack of progress post the NCCN guideline changes suggest previous management were as prepared as a flat-footed deer in the headlights.
There is no question that management change slow things down for a while. That is inevitable. But the lack of preparedness and acceleration in sales seen to date suggest we are unlikely to be any worse off in the long run.
Ann: ImpediMed announces leadership and Board changes, page-34
Add IPD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.9¢ |
Change
0.004(6.15%) |
Mkt cap ! $139.5M | |||
| Open | High | Low | Value | Volume |
| 6.6¢ | 6.9¢ | 6.5¢ | $138.9K | 2.117M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200000 | 6.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.9¢ | 84169 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
6.8¢ |
Change
0.004 ( 4.62 %) |
||||
| Open | High | Low | Volume | ||
| 6.6¢ | 6.8¢ | 6.5¢ | 402373 | ||
| Last updated 15.56pm 14/06/2024 ? | |||||
| IPD (ASX) Chart |